NCT00876421

Brief Summary

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
435

participants targeted

Target at P75+ for phase_2

Geographic Reach
9 countries

50 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

April 2, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 6, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2010

Completed
Last Updated

June 14, 2012

Status Verified

June 1, 2012

Enrollment Period

1 year

First QC Date

April 2, 2009

Last Update Submit

June 12, 2012

Conditions

Keywords

ONO-8539Overactive bladderOAB

Outcome Measures

Primary Outcomes (1)

  • Overactive bladder symptoms

    12 weeks

Secondary Outcomes (1)

  • Overactive bladder symptoms (QOL)

    12 weeks

Study Arms (5)

P

PLACEBO COMPARATOR
Drug: Placebo

A

ACTIVE COMPARATOR
Drug: Tolterodine

E1

EXPERIMENTAL
Drug: ONO-8539

E2

EXPERIMENTAL
Drug: ONO-8539

E3

EXPERIMENTAL
Drug: ONO-8539

Interventions

Placebo / 12 weeks

P

4mg / 12 weeks

A

low dose / 12 weeks

E1

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with medical history of Overactive Bladder symptoms for \> 6 months

You may not qualify if:

  • Patients who have a history or presence of other significant diseases, which in the opinion of the investigator, might compromise the patient's safety or the evaluation of the study results

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (50)

Unknown Facility

Brno, Czechia

Location

Unknown Facility

Jindřichův Hradec, Czechia

Location

Unknown Facility

Olomouc, Czechia

Location

Unknown Facility

Opava, Czechia

Location

Unknown Facility

Pilsen, Czechia

Location

Unknown Facility

Prague, Czechia

Location

Unknown Facility

Štětí, Czechia

Location

Unknown Facility

Ústí nad Labem, Czechia

Location

Unknown Facility

Duisburg, Germany

Location

Unknown Facility

Hagenow, Germany

Location

Unknown Facility

Krumbach, Germany

Location

Unknown Facility

Magdeburg, Germany

Location

Unknown Facility

Mülheim, Germany

Location

Unknown Facility

Weiden, Germany

Location

Unknown Facility

Budapest, Hungary

Location

Unknown Facility

Dombóvár, Hungary

Location

Unknown Facility

Nyíregyháza, Hungary

Location

Unknown Facility

Szeged, Hungary

Location

Unknown Facility

Szekszárd, Hungary

Location

Unknown Facility

Heerlen, Netherlands

Location

Unknown Facility

Maastricht, Netherlands

Location

Unknown Facility

The Hague, Netherlands

Location

Unknown Facility

Tilburg, Netherlands

Location

Unknown Facility

Winterswijk, Netherlands

Location

Unknown Facility

Bialystok, Poland

Location

Unknown Facility

Bielsko-Biala, Poland

Location

Unknown Facility

Gdansk, Poland

Location

Unknown Facility

Gdynia, Poland

Location

Unknown Facility

Katowice, Poland

Location

Unknown Facility

Lodz, Poland

Location

Unknown Facility

Lublin, Poland

Location

Unknown Facility

Mysłowice, Poland

Location

Unknown Facility

Warsaw, Poland

Location

Unknown Facility

Arad, Romania

Location

Unknown Facility

Bihor, Romania

Location

Unknown Facility

Bucharest, Romania

Location

Unknown Facility

Timuș, Romania

Location

Unknown Facility

Moscow, Russia

Location

Unknown Facility

Rostov-on-Don, Russia

Location

Unknown Facility

Saint Petersburg, Russia

Location

Unknown Facility

Gothenburg, Sweden

Location

Unknown Facility

Kungälv, Sweden

Location

Unknown Facility

Stockholm, Sweden

Location

Unknown Facility

Umeå, Sweden

Location

Unknown Facility

Uppsala, Sweden

Location

Unknown Facility

Chernivtsi, Ukraine

Location

Unknown Facility

Donetsk, Ukraine

Location

Unknown Facility

Kharkiv, Ukraine

Location

Unknown Facility

Kyiv, Ukraine

Location

Unknown Facility

Zaporizhzhya, Ukraine

Location

MeSH Terms

Conditions

Urinary Bladder, Overactive

Interventions

Tolterodine TartrateONO-8539

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenylpropanolaminePropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesBenzhydryl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsCresolsPhenols

Study Officials

  • Tomohiro Kuwayama

    Clinical Development, ONO Pharma UK, Ltd

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 2, 2009

First Posted

April 6, 2009

Study Start

April 1, 2009

Primary Completion

April 1, 2010

Last Updated

June 14, 2012

Record last verified: 2012-06

Locations